Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Abstract: Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.

Abstract: Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.

Abstract: Disclosed are oral dosage forms comprising an effective amount of mesalamine, wherein the dosage form has a dissolution profile such that greater than 5 wt % of the total weight of the mesalamine in the dosage form is released during a pH 6.0 portion of a dissolution test, the dissolution test comprising stirring in a pH 6.0 solution for 1 hour, followed by stirring in a pH 7.2 solution for an additional hour. In some embodiments, the dosage form releases less than all of the mesalamine to the right side of the colon. Release of less than all of the mesalamine dosage form to the right side of the colon may be determined by the in vitro dissolution profile of the dosage form.

Abstract: Disclosed herein is a pyrrolopyrazine COMPOUND I having defined amounts of R isomer, particle size, and stability. Also disclosed are pyrrolopyrazine oral dosage forms comprising the described COMPOUND I material as well as methods of treating disorders amenable to therapy using COMPOUND I.

Abstract: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed.

Abstract: This invention relates to a novel dry free-flowing, non-dusty, non-sticky water-soluble granular composition most preferably prepared by extrusion which comprises (a) N-phosphonomethylglycine and/or one or more salts thereof or mixtures thereof, (b) one or more surfactants and (c) an extrusion aid which is solid at ambient temperature, the extrusion aid which further comprises a polyalkylene glycol in which the alkylene oxide units are ethylene oxide, propylene oxide, butylene oxide or a mixture of such oxides.This invention also relates to processes for preparing and to a herbicidal method of using compositions of the invention to kill or control unwanted vegetation by applying an aqueous solution of the composition of this invention to the plants to be killed or controlled.